Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Wilkinson

Showing results (141-150 of 190) with videos related to

Pageof 19
Sort By:
Clinical Pharmacology and Therapeutics|August 1, 1978
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremiaA Rane, J P Villeneuve, W J Stone, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1984
Influence of genetic polymorphism on the metabolism and disposition of encainide in manT Wang, D M Roden, H T Wolfenden, et al.
The Journal of Biological Chemistry|June 3, 1994
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansS M de Morais, G R Wilkinson, J Blaisdell, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1985
Phenotypic differences in mephenytoin pharmacokinetics in normal subjectsP J Wedlund, W S Aslanian, E Jacqz, et al.
Diabetologia|August 1, 1980
Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humansP G Wells, G W Moore, D Rabin, et al.
Anesthesia and Analgesia|October 10, 1997
The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humansC Wandel, S Neff, G Keppler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2000
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testesE F Choo, B Leake, C Wandel, et al.
Clinical Pharmacology and Therapeutics|April 1, 1976
Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in manD G McDevitt, A S Nies, G R Wilkinson, et al.
Cancer Research|October 15, 1987
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factorsA Kaisary, P Smith, E Jaczq, et al.
British Journal of Clinical Pharmacology|December 1, 1980
Propranolol disposition in renal failureA J Wood, R E Vestal, C L Spannuth, et al.
Pageof 19

Showing results (141-150 of 190) with videos related to

Sort By:
Pageof 19
Clinical Pharmacology and Therapeutics|August 1, 1978
Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremiaA Rane, J P Villeneuve, W J Stone, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1984
Influence of genetic polymorphism on the metabolism and disposition of encainide in manT Wang, D M Roden, H T Wolfenden, et al.
The Journal of Biological Chemistry|June 3, 1994
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansS M de Morais, G R Wilkinson, J Blaisdell, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1985
Phenotypic differences in mephenytoin pharmacokinetics in normal subjectsP J Wedlund, W S Aslanian, E Jacqz, et al.
Diabetologia|August 1, 1980
Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humansP G Wells, G W Moore, D Rabin, et al.
Anesthesia and Analgesia|October 10, 1997
The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humansC Wandel, S Neff, G Keppler, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 23, 2000
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testesE F Choo, B Leake, C Wandel, et al.
Clinical Pharmacology and Therapeutics|April 1, 1976
Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in manD G McDevitt, A S Nies, G R Wilkinson, et al.
Cancer Research|October 15, 1987
Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factorsA Kaisary, P Smith, E Jaczq, et al.
British Journal of Clinical Pharmacology|December 1, 1980
Propranolol disposition in renal failureA J Wood, R E Vestal, C L Spannuth, et al.
Pageof 19